Alterity Therapeutics Ltd Stock Price, News & Analysis

Alterity Therapeutics (NASDAQ: ATHE) announced positive topline data from its ATH434-202 open-label Phase 2 clinical trial for treating Multiple System Atrophy (MSA). The trial demonstrated that ATH434 reduced disease progression by approximately 50% compared to historical controls over 12 months, as measured by the Modified Unified MSA Rating Scale Part I.

Key findings include: 30% of participants reported stable neurological symptoms, stabilization of orthostatic hypotension symptoms, and slowed brain atrophy in MSA-affected areas. The drug showed a favorable safety profile with no serious adverse events related to treatment. Importantly, these results were consistent with the company's previous double-blind Phase 2 trial (ATH434-201), supporting the advancement of ATH434 in MSA treatment.

Alterity Therapeutics (NASDAQ: ATHE) has announced the publication of a groundbreaking study in the Annals of Clinical and Translational Neurology, introducing the MSA Atrophy Index (MSA-AI), a novel MRI-based measurement tool for Multiple System Atrophy (MSA).

The research, developed through Alterity's bioMUSE Natural History Study, employs deep learning methods to track brain atrophy in MSA patients. The study demonstrated that MSA-AI can effectively distinguish MSA from related conditions like Parkinson's disease and Dementia with Lewy Bodies, with significantly lower scores indicating reduced brain volumes in MSA patients (p < 0.001).

Importantly, the study revealed that 12-month brain volume reductions correlated with clinical disease worsening. This innovative tool will be implemented in Alterity's Phase 2 clinical program and future Phase 3 trials for patient selection and disease progression monitoring.

Alterity Therapeutics (NASDAQ: ATHE) has announced that CEO David Stamler will participate in a Fireside Chat hosted by MST Access on June 25, 2025 (Australia) / June 24, 2025 (US). The presentation will focus on providing updates regarding the company's ATH434 development program in Multiple System Atrophy, following the release of positive Phase 2 data in January. The webcast will take place at 9:00 a.m. AEST for Australian participants and 4:00 p.m. PT / 7:00 p.m. ET for US participants. Registration is required for attendance, and a recording will be made available on the company's website.

Alterity Therapeutics (NASDAQ: ATHE) presented significant findings at the 2025 International MSA Congress regarding their ATH434 Phase 2 clinical trial and related MSA research. The ATH434-201 trial demonstrated promising results, with the 50mg dose showing a 48% relative treatment effect (p=0.02) and the 75mg dose showing a 30% effect (p=0.16) in reducing disease severity on the UMSARS I scale. The drug was well-tolerated with no serious adverse events.

Key research presentations included the development of the MSA Atrophy Index (MSAai), a new imaging biomarker for improved MSA diagnosis and monitoring, and findings from the bioMUSE Natural History Study showing increased α-synuclein levels in skin correlating with greater orthostatic symptoms. The study also demonstrated ATH434's ability to stabilize or reduce iron accumulation in affected brain regions and showed trends in reducing brain atrophy at both dose levels.

Alterity Therapeutics (NASDAQ: ATHE) announced multiple presentations at the 2025 International MSA Congress in Boston, highlighting their clinical programs in Multiple System Atrophy (MSA). The company will present Phase 2 data for ATH434, their lead candidate that recently received Fast Track Designation from the FDA. Dr. David Stamler, CEO, will deliver a plenary presentation on how "ATH434 Slowed Disease Progression in Phase 2 Study." The congress will also feature research from Vanderbilt University Medical Center collaborators on MSA biomarkers. ATH434 is an oral agent designed to inhibit pathological protein aggregation in neurodegeneration by restoring brain iron balance. The drug has shown positive results in Phase 2 trials, demonstrating clinical efficacy, target engagement, and favorable safety. ATH434 has received both FDA and European Commission Orphan Drug Designation for MSA treatment.

Alterity Therapeutics (NASDAQ: ATHE) has received Fast Track designation from the FDA for its drug candidate ATH434 in treating Multiple System Atrophy (MSA). This designation, complementing their existing Orphan Drug Designation, aims to accelerate the development and review process for ATH434, recognizing its potential as an innovative treatment for MSA - a condition currently without approved therapies.

CEO David Stamler highlighted that the Fast Track status validates ATH434's promise, supported by recent scientific findings on its mechanism of action and positive results from their double-blind Phase 2 clinical trial. The designation enables more frequent FDA interactions, potentially expediting the drug's development and approval pathway.

Alterity Therapeutics reported positive results from its ATH434-201 Phase 2 clinical trial for Multiple System Atrophy (MSA) treatment. The trial demonstrated a significant 48% reduction in disease severity at 50mg dose and 30% at 75mg dose compared to placebo.

Key financial highlights include a cash balance of A$17.96M as of March 31, 2025, with an additional A$27.1M raised after the quarter end. Operating cash outflows were A$0.73M for Q3 FY25.

The company completed its ATH434-202 open-label trial in advanced MSA patients in March 2025, with topline data expected mid-year. The drug showed positive results in clinical efficacy, including improvements in daily living activities, severity assessment, and increased patient activity levels measured by wearable sensors. ATH434 was well-tolerated with no serious adverse events attributed to the treatment.

Alterity Therapeutics (NASDAQ: ATHE) presented Phase 2 clinical trial results for ATH434-201 at the MSA Research Symposium. The double-blind study, involving 71 patients, demonstrated significant efficacy in treating Multiple System Atrophy (MSA).

Key findings include:

• 48% relative treatment effect at 50mg dose (p=0.02) and 30% at 75mg dose (p=0.16) on UMSARS I scale
• Improvement in Clinical Global Impression of Severity Scale at both doses
• Enhanced patient mobility metrics including step count and walking time
• Positive results in reducing brain atrophy and stabilizing iron levels in affected brain regions

The treatment was well-tolerated with similar adverse event rates to placebo, with no serious adverse events attributed to ATH434. The strong clinical efficacy data and novel mechanism support continued advancement of ATH434 for MSA treatment.

Alterity Therapeutics (NASDAQ: ATHE) has presented new data from its ATH434 Phase 2 trial for Multiple System Atrophy (MSA) at the American Academy of Neurology 2025 Annual Meeting. The double-blind study showed promising results with clinically meaningful efficacy across multiple measures.

Key findings include:

• 48% decrease in clinical progression at 50mg dose (p=0.02) and 30% decrease at 75mg dose using modified UMSARS I rating scale
• Improvement in Clinical Global Impression of Severity Scale at 50mg dose (p=0.0088)
• Positive trends in Orthostatic Hypotension Symptom Assessment
• Increased activity levels measured by wearable sensors, including improved step count, walking time, and standing time

The imaging outcomes in 61 participants demonstrated that ATH434 reduces iron signal in MSA-affected brain regions. Additionally, results from the bioMUSE natural history study supported the utility of wearable sensors in MSA trials, showing correlations between sensor-derived metrics and clinical evaluations.